Filing Details

Accession Number:
0000014272-16-000294
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-19 16:32:34
Reporting Period:
2016-02-17
Filing Date:
2016-02-19
Accepted Time:
2016-02-19 16:32:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
14272 Bristol Myers Squibb Co BMY Pharmaceutical Preparations (2834) 220790350
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1199294 Sandra Leung Bristol-Myers Squibb Company
345 Park Avenue
New York NY 10154
Evp, General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.10 Par Value Acquisiton 2016-02-17 14,560 $22.73 319,699 No 4 M Direct
Common Stock, $0.10 Par Value Disposition 2016-02-17 10,152 $63.57 309,547 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, $0.10 Par Value Option (right to buy) Disposition 2016-02-17 14,560 $0.00 14,560 $22.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-03-06 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.10 Par Value 5,699 Indirect By BMY Savings and Investment Program
Footnotes
  1. A portion of these shares were sold to cover exercise price and taxes in accordance with broker's procedure for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $63.56 to $63.57, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  2. Based on a plan statement as of the end of the most recent fiscal quarter.
  3. All of the shares are currently exercisable.